Micro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice

Buel D. Rodgers, Yemeserach Bishaw, Denali Kagel, Julian N. Ramos and Joseph W. Maricelli

Micro-dystrophin (µDys) gene therapeutics can improve striated muscle structure and function in different animal models of Duchenne muscular dystrophy. Most studies, however, used young mdx mice that lack a pronounced dystrophic phenotype, short treatment periods, and limited muscle function tests. We, therefore, determined the relative efficacy of two previously described µDys gene therapeutics (rAAV6:µDysH3 and rAAV6:µDysS) in 6-month-old mdx mice using a 6-month treatment regimen and forced exercise. Forelimb and hindlimb grip strength, metabolic rate (VO₂ max), running efficiency (energy expenditure), and serum creatine kinase levels similarly improved in mdx mice treated with either vector. Both vectors produced nearly identical dose-responses in all assays. They also partially prevented the degenerative effects of repeated high-intensity exercise on muscle histology, although none of the metrics examined was restored to normal wild-type levels. Moreover, neither vector had any consistent effect on respiration while exercising. These data together suggest that, although µDys gene therapy can improve isolated and systemic muscle function, it may be only partially effective when dystrophinopathies are advanced or when muscle structure is significantly challenged, as with high-intensity exercise. This further suggests that restoring muscle function to near-normal levels will likely require ancillary or combinatorial treatments capable of enhancing muscle strength.

INTRODUCTION
Most muscular dystrophies result from abnormalities in the structure and function of the multi-protein dystrophin–glycoprotein complex. The most common forms, Duchenne and Becker muscular dystrophies (DMD and BMD, respectively), result from genetic anomalies within the X-linked dystrophin gene and, together, occur at an approximate frequency of 1 in every 5,000 male births. The two forms, however, differ in prognosis, which is dependent upon the relative amount of functioning dystrophin protein expressed in striated muscle. Disease progression is rapid and the pathologies are more severe in Duchenne patients who express little to no functioning dystrophin, whereas in Becker patients, truncated dystrophins or low protein levels partially protect striated muscle. Despite these differences, both DMD and BMD are primarily treated with palliative care and corticosteroids as no currently available treatment can compensate for the loss of functioning dystrophin. Developing treatments include novel gene therapeutics as several preclinical studies very clearly illustrate the corrective potential of adeno-associated viral vectors (AAVs) carrying “micro-dystrophin” (µDys) cDNA payload genes. The approximately 13.9-kb dystrophin cDNA size greatly exceeds the 5-kb packaging capacity of AAVs. Nevertheless, µDys, mini-dystrophin, or reconstituted full-length dystrophin cDNAs have proven highly effective in restoring muscle structure and many aspects of muscle function when delivered using an AAV vector. Indeed, three different µDys gene therapeutics are currently being developed by Solid Biosciences, Sarepta/Nationwide Children’s Hospital, and Pfizer. Each therapeutic contains µDys cDNA constructs coding for truncated dystrophin proteins that lack several internal repeating motifs. These proteins retain amino- and carboxy-terminal cysteine-rich domains (Figure 1) critical for binding to intracellular γ-actin and to the glycoprotein complex on the muscle cell plasma membrane (i.e., sarcolemma). This provides a functional link between the muscle contractile elements within the cell and the lateral membrane anchoring components, which, in turn, stabilizes the muscle cell and prevents contraction-induced muscle damage and, ultimately, degeneration.

Recent studies compared the efficacy of several novel µDys gene therapeutics in mdx mice. Each µDys protein contained functional domains that were either lacking in previously developed versions or that were placed within different intramolecular contexts. They all retained preserved regions for binding to γ-actin and β-dystroglycan and, in addition, contained different combinations of spectrin-like repeats (R1–R24) from the internal rod domain (Figure 1A). Other domains...
were incorporated and included two or three of the hinge domains (H1–H4) that contribute to protein flexibility. Repeats R16–R17 were also included as they are necessary for neural nitric oxide synthase (nNOS) localization to the dystrophin glycoprotein complex at the sarcolemma.12–14 One of the constructs tested here, \( \mu \text{DysH3} \), is structurally similar to that being developed by Sarepta/Nationwide Children’s Hospital (ClinicalTrials.gov: NCT03375164) and differs only by a switched hinge domain, H3 for H2.15 Unlike \( \mu \text{Dys5} \), which is being developed by Solid Biosciences (SGT-001; ClinicalTrials.gov: NCT03368742), neither of these constructs contain R16 and R17 (Figure 1B). Thus, it is possible that they provide more flexibility due to the additional hinge domain but lack an nNOS binding domain that can preserve contraction-induced vasodilation, thereby preventing ischemic damage.13 Both \( \mu \text{DysH3} \) and \( \mu \text{Dys5} \), however, lack H2 and should not produce a ringbinden phenotype.15,16

These recent studies suggest that refinements to the rod domain alone can significantly improve the functionality of \( \mu \text{Dys} \) gene therapeutics when compared to the previously established “best” candidate, \( \mu \text{DysH3} \).11 They identified two constructs that performed slightly better than the others and this includes \( \mu \text{Dys5} \). However, these studies were performed using very young mice (2 weeks old), as do most preclinical studies for DMD, and only minimal tests of muscle function (specific force and contraction-induced injury). Such assessments are highly appropriate for establishing proof of concept and for comparing the relative efficacy of different therapeutics, but their results may not translate to clinical success as the development of pathophysiological signs in any dystrophic model accumulates with age. More comprehensive studies of older dystrophic mice using rigorous tests of muscle function are, therefore, needed to adequately determine the relative effectiveness of any treatment.
We compared μDysH3 and μDys5 gene therapeutics using older adult mdx mice and chronic exercise exacerbation as this produces a dystrophic phenotype that more closely resembles the human condition.17-21 Our experimental design incorporated a long treatment period of 6 months and tests of systemic muscle function that resemble those used in clinical trials (e.g., 6-minute walk test, respiratory function, grip strength). Our results indicate that both therapeutics were only partially effective at the doses tested. Nevertheless, they also indicate that ancillary support may be needed to compensate for the accumulated effects of muscle degeneration over time.

RESULTS
Study Design
Experiments were performed on untreated wild-type C57BL/10 control mice and on treated and untreated mdx mice. Mice were first analyzed and treated when 6 months old and were terminated when 12 months old (Figure 1C). Compared to young adult mdx mice (e.g., 2–3 months old), such older adult mice express a more pronounced dystrophic phenotype but are still capable of completing rigorous exercise protocols.19,21 Grip strength measures were collected on all mice before injecting the treated groups, which received retro-orbital (RO) injections of low (5 × 10^{11} vg per mouse) or high (5 × 10^{12} vg per mouse) doses of rAAV6:μDys5 or rAAV6:μDysH3 immediately after assessing initial fore- and hindlimb grip strength. Such measures were subsequently collected monthly for 6 additional months. During the final month, mice exercised twice weekly on respiratory treadmills, with 2 and 3 days of rest between exercise sessions. Finally, grip strength measurements were collected immediately before the last VO_{2} max test, and mice were subsequently terminated after 24 hr.

Grip Strength
When the study began, absolute forelimb and hindlimb grip strength of wild-type mice (WT, injected with 0 vg) CS7BL/10 and mdx mice injected with all doses (mdx = 0 vg), (E and F) Percent change in absolute forelimb (E) and hindlimb (F) grip strength from the initial measurements (time 0). The only difference between vectors occurred in (B) (μDysH3-H > μDys5-H) at 10 and 11 months. Otherwise, significant differences between dose groups are indicated by letters as follows: a, WT differs from all other groups; b, WT differs from all others, and low doses differ from high and mdx; c, WT differs from others, and both doses differ from mdx; d, WT differs from low doses; e, WT differs from low doses and mdx, while both doses differ from mdx; f, mdx differs from all others; g, WT and high doses differ from others, and low doses differ from mdx; h, the dose groups, WT, and mdx all differ from each other; i, high and low doses both differ from all others; j, high doses and mdx differ from others; k, no differences; l, high doses differ from others.
improved $\text{VO}_2\max$ only occurs with repeated high-intensity interval training and has not been demonstrated in wild-type or $mdx$ mice using the protocol described herein.20,26,27 However, the initial and final $\text{VO}_2\max$ values were not significantly different in $mdx$ mice receiving high-dose vector treatment. Note that the relative change in $\text{VO}_2\max$ among these groups was nearly identical to that of wild-type mice, just one third, and significantly different from the change in untreated $mdx$ mice (Figure 3B). These results are highly novel and suggest that, even in older $mdx$ mice, high-dose vector treatment can prevent the deleterious effects of exercise-induced muscle damage and preserve maximal exercise capacity as measured by $\text{VO}_2\max$. The differences in total distance traveled (Figures 3C and 3D) resembled those of $\text{VO}_2\max$, and although many were not significant, the overall similar pattern further highlights the beneficial effects of uDys gene therapy on exercise performance.

The reduced exercise capacity among all $mdx$ mice is possibly best illustrated by the total energy expended during the initial $\text{VO}_2\max$ test (Figure 3E). In fact, there were no differences in the total energy expended among the groups, despite the fact that treated and untreated $mdx$ mice ran shorter distances. In the final $\text{VO}_2\max$ test, the energy expended was lower in all but wild-type mice (Figures 3E and 3F). This was consistent with mice running shorter distances except in mice receiving high doses of either vector where, in comparison to the other groups, the relationship between distance traveled and energy expended were inversely correlated. These mice ran similar or longer distances than the others but expended fewer calories (Figure 3G). This is best illustrated by the energy expenditure rate, an inverse measure of running efficiency, which increased in all groups between tests except in $mdx$ mice treated with high doses. Indeed, the rate decreased by 13% and 20% in mice treated with rAAV6:uDys5-H and rAAV6:uDysH3-H, respectively (Figure 3H). This indicates that high-dose treatment of either vector improved running efficiency as mice ran farther while consuming less energy.

Exercise Training

Previous studies identified pathological markers of exercise training in the $mdx$ mouse and in the P448L mouse, a model for limb girdle muscular dystrophy 2i.20,28 The markers include motivational shock accumulation, $\text{VO}_2\text{cv}$ ($\text{VO}_2$ coefficient of variation, a measure of $\text{VO}_2$ variability during exercise), minimum $\text{VO}_2$, and maximum respiratory exchange ratio. Throughout the 4-week period, the number of accumulated shocks increased in all groups. The rate of increase was not equal, however, as the final number in $mdx$ mice treated with no or low-dose vectors was 4-fold higher than that of wild-type mice (Figure 4A). Most importantly, treating $mdx$ mice with high doses of either vector significantly reduced shock numbers compared to these groups, although shock levels remained 3-fold higher than those in wild-type mice.

This pattern of responsiveness is similar to the patterns previously discussed where treating with high vector doses improves but does not restore muscle function, although other aspects of exercise training were, for the most part, unaffected by any treatment. This

---

**Table 1. Change in Body Mass**

|            | WT     | Mdx    | µDys5-L | µDys5-H | µDysH3-L | µDysH3-H |
|------------|--------|--------|---------|---------|----------|----------|
| Initial    | 23.4±0.3| 24.0±0.2| 22.2±0.3| 23.2±0.3| 23.5±0.3| 24.2±0.2|
| Final      | 25.8±0.3| 27.3±0.2| 26.5±0.3| 25.2±0.3| 26.8±0.3| 25.7±0.2|
| % change   | 10.3±0.1| 13.5±0.2| 14.3±0.3| 6.6±0.3 | 14.1±0.3| 6.3±0.1 |

---

wild-type mice at several time points, especially at and after 3 months. Normalizing the forelimb data to body mass helped distinguish differences between high and low doses, but not between vectors, as the high doses of both vectors restored strength to wild-type levels, while the low doses only partially restored strength (Figure 2C).

Normalizing these data to body mass is somewhat misleading as the body composition and mass of older wild-type and $mdx$ mice often differ and can change disproportionately (Table 1). In fact, the similarities in forelimb grip strength among wild-type mice and $mdx$ mice treated with high doses of either vector are due, in part, to normalization, as the body mass of the former increased by approximately 10% and that of the latter increased by 6%. This suggests that treating mice with high vector doses enhanced, but did not completely restore, forelimb strength to normal. Tracking relative changes of normalized forelimb grip strength over time further distinguished the high-dose groups from all the others (Figure 2E). Indeed, strength increased and was maintained in these mice, although there was a net decrease in the other groups.

Over the first 4 months, absolute hindlimb grip strength steadily increased in all groups (Figure 2B), which typically occurs in our experience as mice slowly become accustomed to the assay. Normalizing grip strength identified differences similar to those of the forelimb measures, as again, no differences were detected between the vectors and the low-dose treatment had no significant effect while the high doses progressively increased strength. Moreover, high-dose treatment fully restored strength in 4 months, although it declined significantly thereafter, a pattern that also occurred when plotting relative changes (Figures 2D and 2F). The latter results are possibly the most informative and very clearly indicate greater responsiveness among the high-dose groups, despite the fact that both fore- and hindlimb grip strength began to decline after 3 or 4 months, even in these groups. Nevertheless, as a whole, the grip strength results together suggest that high doses of either vector are needed to have long-term effects on partially restoring grip strength, at least in this particular (i.e., aged) dystrophic mouse model.

**Exercise Capacity**

The initial $\text{VO}_2\max$ of all $mdx$ mice, treated or not, was significantly lower than that of wild-type mice (Figure 3A). Five months of µDys gene therapy was, therefore, incapable of maintaining $\text{VO}_2\max$ in 11-month-old mice. Due to the older age of mice when the exercise protocol began, the $\text{VO}_2\max$ of most mice, including wild-type mice, decreased from initial to final tests. This was not unexpected as
includes the respiratory metrics as well as total energy expended (Figures 4B–4F). In fact, very few differences were noted regardless of metric, training session, or group comparison. This differs from our previous studies of young dystrophic mice where all of these metrics differed between dystrophic and wild-type mice, suggesting that advanced age is itself a confounding factor. Nevertheless, both doses of both vectors partially restored VO₂ CV for the entire study period as values for treated mdx mice were different from both wild-type and untreated mdx mice (Figure 4B).

**DISCUSSION**

Because the dystrophic phenotype in mdx mice progressively develops, many pathologies commonly expressed even in young DMD patients are not expressed in young mdx mice (fibrosis, muscle hypertrophy, cardiac dysfunction, etc.). Thus, the older mdx mouse is, in many ways, a superior preclinical model to the more commonly used young mdx mouse. Early expression of disease pathologies can also be induced with high-intensity exercise. In fact, the TREAT-Neuromuscular Disease (TREAT-NMD) network recommends using exercise as a quantitative endpoint in preclinical studies with mdx mice. TREAT-NMD also provides several standardized protocols for testing mdx mice, including forced exercise and quantifying respiratory and exercise performance. Our combined use of older mdx mice and forced treadmill running, therefore, represents a rigorous attempt to accurately represent a more clinically relevant condition where muscle structure and function are compromised from the accumulated effects of muscle degeneration.

Both gene therapeutics tested significantly enhanced various aspects of skeletal muscle structure and function, although the low doses tested had minimal significant effects on just a few variables quantified (e.g., grip strength at some time points, measures of muscle size in some muscles, VO₂ CV). By contrast, the high doses were effective overall at enhancing or preserving measures of grip strength and exercise capacity (e.g., VO₂ max, distance traveled, metabolic rate, shock accumulation) while also preserving muscle fiber size and preventing some degeneration (i.e., central nucleation). This protective-ness, however, was only partially effective, as none of the metrics measured was restored to healthy wild-type levels at the doses used here, which has been previously noted in other studies using aged mdx mice.

Gregorevic et al.²² treated 20-month-old mdx mice for 4 months with 1 × 10¹³ vg of a “first-generation” µDys vector and reported partial effectiveness. The specific µDys expressed in this study (ΔR4-23/ΔCT; Figure 1B) is structurally similar to µDysH3 but contains H2 instead of H3. It also similarly restores some muscle function in side-by-side comparisons, although animal studies indicate that it can produce ringed fibers with contraction-induced injury.¹⁵ Gregorevic et al.²² reported that the body mass of treated mdx mice was slightly higher than that of untreated mdx mice and was restored to only 50% of wild-type levels. Serum CK levels were substantially reduced but remained elevated. The fiber size distribution, central nucleation, and specific force of TA or diaphragm muscles were either not affected by the treatment or were only minimally affected, and although treated diaphragms were protected from contraction-induced injury, TA muscles were not.

Gregorevic et al.²² administered a suboptimal dose (producing fewer than 100% transduced fibers) that is 2-fold higher than the highest dose used herein, yet they also reported partial restoration of muscle structure and function. Partial restoration of the cardiac phenotype in aged mdx mice was also reported using 5 × 10¹² vg of a cardiac-optimized µDys and AAV9 serotype vector.²³,²⁴ This is contrasted by earlier studies with young mice where a more complete restoration was demonstrated.³⁶ Wasala et al.³⁷ recently reported that the cardiac-specific overexpression of a mini-dystrophin in 22-month-old transgenic mdx mice normalized ECG abnormalities and improved...
cardiac hemodynamics, despite the fact that heart rate, QRS interval, and Q wave amplitude were only partially corrected. Furthermore, hemodynamics were improved, but far from normalized, and the hearts themselves were hypertrophic.

All of this together suggests that the partial amelioration of dystrophic pathologies in older mdx mice is actually the norm at medium to high vector doses. It even occurs in many preclinical studies with young mdx mice, further indicating that ancillary treatments are needed to maximize the corrective potential of replacement gene therapy for muscular dystrophy. This is particularly true when using a rigorous model system like older mice and exercise-induced injury that more closely mimic the clinical condition where the accumulated pathologies in older hearts themselves were hypertrophic.

Ancillary or combinatorial approaches that complement μDys gene therapeutics are hardly novel as previous studies clearly demonstrated the benefit of co-delivering a muscle growth promoter, like follistatin or insulin-like growth factor 1 (IGF1), along with μDys in mdx mice,38–40 In fact, an AAV-based follistatin gene therapeutic has already been tested in phase I and phase IIa clinical trials as a sole treatment for BMD.41 Follistatin binds and antagonizes ActRIib ligands, including myostatin, GDF11, and activin,42 and successfully improved muscle function in these trials. It also improved muscle function in preclinical proof-of-concept studies with mdx mice,43–48 and its use as a co-therapeutic is superior to that of μDys gene therapy alone.49 These latter studies demonstrated complete restoration of skeletal-muscle-specific force and resistance to contraction-induced injury in 23-month-old mdx mice, whereas μDys gene therapy alone had minimal effects. However, follistatin’s promiscuity for multiple ActRIib ligands requires it to be administered intramuscularly, as targeting the ligands in circulation via any number of approaches (immunoneutralization, ligand traps, follistatin, etc.) has the potential to produce very serious off-target effects or to be less effective.49–51 By contrast, we recently developed a Smad7 gene therapeutic (AVGN7) that attenuates the intracellular signaling pathways of ActRIib receptors in striated muscle and, as a result, avoids these off-target effects and enhances striated muscle mass and function as well as exercise and cardiac capacity.52,53 Future studies will, therefore, evaluate the efficacy of a combinatorial approach that co-delivers AVGN7 with one of the μDys vectors described herein.

Both rAAV6:μDys5 and rAAV6:μDysH3 proved to be similarly effective in nearly all of the assessments. This was not entirely unexpected, as although μDys5 was one of the two top-performing micro-dystrophins tested in a recent comparison by Ramos et al.,11 it was not able to produce a full functional correction. It did, however, localize nNOS to the sarcolemma, and although physiological responses to this were not directly measured, other studies indicate that ischemia and edema are prevented by such actions.12,54 Ramos et al.11 also reported that gastrocnemius-specific force was similar in mice treated with rAAV6:μDys5 or rAAV6:μDysH3, while resistance to contraction-induced injury was virtually identical whether gastrocnemius or

Figure 3. Metrics of Exercise Capacity
VO2 max tests were performed on wild-type (WT) and mdx mice, 5 (initial) and 6 (final) months after injecting with 0.5 × 1011 (low dose, -L), or 5 × 1012 (high dose, -H) vg of rAAV6:μDys5 (μDys5) or rAAV6:μDysH3 (μDysH3) (see Figure 1). WT and mdx mice were injected with 0 vg, the key in (A) applies to the whole figure, and each histogram bar represents mean ± SEM (n = 4–6). [A and B] VO2 max (A) and the change from initial to final (B). (C and D) Distance traveled before mice fatigued (C) and the change from initial to final (D). (E and F) Indirect calorimetry was used to calculate the total energy expended (E) and the change from initial to final (F). (G and H) The energy consumption rate was then calculated by normalizing energy expenditure values to total distance traveled (G) and the change in the energy consumption rate (H). Significant differences between any two groups (p ≤ 0.05) are indicated by different letters, whereas shared letters indicate no difference.
diaphragm muscles were used. In addition, Ramos et al. treated 2-week-old mdx4cv mice with 1 \times 10^{11} \text{vg} per mouse, whereas we treated 24-week-old mdx mice with half as much vector. Although mdx4cv mice express a more severe phenotype at an earlier age, the older mdx mice were likely more debilitated, especially as exercise was used to exacerbate the phenotype. Thus, the similar responsiveness to rAAV6:μDysH3 and rAAV6:μDys5 in the present study could be explained by the use of animals that are more severely debilitated as well as the use of relatively lower vector doses; the challenge was simply too significant to distinguish subtle differences in efficacy. Because cardiac and respiratory failure is ultimately responsible for morbidity and mortality among DMD patients, the significant effects of high-dose vector treatment on metrics of exercise capacity, especially VO2 max and energy expenditure rate, are particularly important. Indeed, changes in these factors are primarily influenced by cardiac rather than skeletal muscle function, unless the former has been optimized with training, which did not occur in the present study and, according to our previous study, is unlikely to occur even in young mdx mice. This suggests that both μDys gene therapeutics have the potential to address the primary cause of death in DMD patients. It also suggests that the non-significant differences between rAAV6:μDys5 and rAAV6:μDysH3 could have practical consequences, although such reasoning naturally assumes that the treatment efficacy described for mice will translate in clinical trials.

The clinical success of DMD therapeutics may very well depend upon their ability to ameliorate advanced pathologies as the disease is typically diagnosed well after many disease symptoms are noticed. Patients are historically diagnosed at the average age of 5 years, although some are diagnosed much later even in their mid-20s. Furthermore, the delay between the expression of early stage pathologies (lethargy, weakness, hypertrophied calf muscles, etc.) and official diagnosis is often many years, during which the disease progression worsens. All of this suggests that proof-of-concept studies of μDys gene therapeutics with older mdx mice may be more predictive of clinical success than those using young mouse models. Such reasoning applies to other disease interventions (different μDys
gene therapeutics, gene editing, exon skipping, etc.) as well. It also supports the use of ancillary approaches to enhance dystrophic muscle function, as no therapy to date has ever restored dystrophic muscle function to non-diseased levels.

MATERIALS AND METHODS

Vector Construction

The recombinant AAV6 μDys vectors reported herein were prepared in the vector core of the Sen. Paul D. Wellstone Muscular Dystrophy Specialized Research Center at the University of Washington, as previously described. Briefly, a custom AAV transfer plasmid containing the previously described muscle-specific CK8 regulator cassette, cDNA expression constructs for μDys5 and μDysH3, and flanking AAV serotype 2 inverted terminal repeats was constructed using standard recombinant methodology. The resulting plasmids, pAAV-CK8-μDys5 and pAAV6-CK8-μDysH3, were then used to co-transfect HEK293 cells with pDGM6 packaging plasmids. Recombinant vectors were subsequently purified from conditioned medium using ion exchange and heparin chromatography followed by CsCl gradient centrifugation to remove empty AAV6 capsids. Concentrated stocks of vector were then suspended in PBS and stored at −80°C until use.

Animal Care

Breeding colonies of wild-type C57BL/10 and dystrophic mdx mice were maintained in environmentally controlled rooms of an accredited vivarium, under a 12-h:12-h light:dark cycle at Washington State University. Male mice were provided food and water ad libitum and were randomly assigned to treated and untreated groups (n = 6) when 6 months old. Maintenance and use of these mice was performed according to a protocol preapproved by an institutional animal care and use committee that met all requirements specified by the Guide for the Care and Use of Laboratory Animals. Prior to treatment, forelimb and hindlimb grip strength measures were recorded for 6-month-old mice as described later. The mdx mice were then anesthetized via an intraperitoneal (i.p.) injection of 0.25 mg/g tribromoethanol (Avertin) and subsequently injected retro-orbitally with $5 \times 10^{11}$ vg (2–2.2 × $10^{13}$ vg/kg body mass) or $5 \times 10^{12}$ vg (2–2.2 × $10^{14}$ vg/kg) rAAV6-μDys5 or rAAV6-μDysH3 in a total volume of 150 μL sterile PBS. These doses have been extensively used and were chosen to help distinguish differences between groups.

Figure 5. Histopathological Metrics
(A–D) Fiber and nuclei counts per field in different skeletal muscles (TA, tibialis anterior; GAST, gastrocnemius; QUAD quadriceps; and DIA, diaphragm) of wild-type (WT) and mdx mice injected with 0, $5 \times 10^{11}$ (low dose, -L), or $5 \times 10^{12}$ (high dose, -H) vg of rAAV6-μDys5 (μDys5) or rAAV6-μDysH3 (μDysH3). (A) Total nuclei. (B) Fibers with central nuclei. (C) Central nuclei. (D) Fiber count. WT and “mdx” mice were injected with 0 vg, the key in (A) applies to the whole figure, and each histogram bar represents mean ± SEM (n = 4–6). (E–G) Fiber cross-sectional area (CSA) of (E) TA, (F) GAST, and (G) QUAD muscles parsed by fiber size groups: <3,000 μm², small; 3,001–7,000 μm², medium; and >7,000 μm², large. (H) Mice were sacrificed, and serum was collected 24 h after the final VO₂ max test to quantify serum CK levels. Significant differences (p < 0.05) between any two groups are indicated by different letters, whereas shared letters indicate no difference.
vectors, as the use of sub-optimal doses—those that do not transduce 100% of the fibers—are more likely to identify differences between vectors when assays that produce sigmoidal response curves are used. Additional groups of untreated wild-type and mdx mice were also included as controls.

**Grip Strength**

Grip strength was quantified on a monthly basis using the Columbus Instruments Grip Strength Meter (Columbus, OH, USA). Forelimb measurements were collected by gently pulling the mouse backward by the tail until the front paws released the T-bar attachment. A mesh attachment was used for collecting hindlimb measurements. Mice were scruffed, hindpaws were raked across the mesh, and then grip strength was again recorded during the release. For both assays, grip measurements were replicated 5 times each session, with intervals at a minimum of 1 min between replicates. This ensures accuracy, reduces variability, and prevents habituation. Mean values were calculated for each mouse at each time point. These values were then used to create in-group replicates.

**Forced Treadmill Exercise**

A four-lane Oxymax FAST Modular Treadmill System from Columbus Instruments (Columbus, OH, USA) was used to quantify different metrics of exercise capacity and respiration using a protocol optimized for mdx mice as previously described. Motivational shock units were programmed to administer a 0.65-mA shock for 200 ms at a frequency of 1 Hz, and airflow through the treadmill chambers was set at a rate of 0.6 L/min. Mice were acclimated to treadmills by walking at 5 m/min for 5 min on 3 consecutive days. Mice then began exercise training with an initial VO2 max test that was followed by 6 training sessions and a final VO2 max test (Figure 1C).

Both VO2 max tests were performed at a 25° incline. Mice ran 5-min intervals of 5, 9, 12, and 15 m/min. The treadmill speed then increased 1.8 m/min every 2 min until mice reached exhaustion (i.e., failure to reengage the treadmill for 10 consecutive seconds). When this occurred for a particular mouse, the shock unit was deactivated. VO2 max was confirmed by the respiratory exchange ratio (RER) approaching 1.1 and a concurrent VO2 peak. Caloric expenditure was calculated using $CV = 3.815 + 1.232 \times \text{RER}$, which was derived from the linear positive correlation between heat per liter of O2 (in kilocalories). This, in turn, was calculated using $\text{heat} = CV \times \text{VO2}_{max}$, and total energy expenditure (in kilocalories). For the 6 training sessions, mice ran on a 0° incline for 2 min at 5 m/min, 5 min at 8 m/min, 5 min at 12 m/min, and then 20 min at 15 m/min, all of which is submaximal effort compared to VO2 max testing.

**Muscle Histology and Serum CK Assays**

Mice were sacrificed 24 h following the final VO2 max test. Quadriceps, gastrocnemius, tibialis anterior, diaphragm muscles, and hearts were flash frozen in −140°C isopentane. Muscles were sectioned on a cryostat (10-μm sections) and, prior to staining, sections were fixed for 10 min in 4% paraformaldehyde and then stained with H&E to quantify total fibers, central nuclei, and cross-sectional area. When quantifying nuclei, no empty spaces were included in the field of view, as it was filled with muscle tissue, allowing us to normalize nuclei counts to the field rather than to a specific area. Fiber and central nuclei counts were obtained using Adobe Photoshop, while the cross-sectional area was obtained using ImageJ. Blood was collected via cardiac puncture, and clots were allowed to form while samples rested on ice. Samples were then centrifuged at 10,000 rpm for 10 min, and serum was collected. CK levels were then quantified using a colorimetric assay (Abcam) following the manufacturer’s instructions.

**Statistical Analysis**

Statistical analyses were performed using Prism (GraphPad Software; La Jolla, CA, USA). Significant differences were determined using a normal or repeated-measures ANOVA (one- or two-way) as needed. Tukey’s test for multiple mean comparisons was then used to identify differences between means. Values are presented as mean ± SEM, and significance was accepted at $p \leq 0.05$. In the figures, differences between means are often indicated by different letters as defined in the legends. These definitions often differ between figures and panels (e.g., different letters signify a difference, each letter represents a specific comparison, etc.).

**AUTHOR CONTRIBUTIONS**

Conceptualization, J.W.M. and B.D.R.; Methodology, B.D.R., J.W.M., Y.B., D.K., and J.N.R.; Investigation, J.W.M., Y.B., and D.K.; Formal Analysis, B.D.R. and J.W.M.; Writing – Original Draft, B.D.R.; Writing – Review & Editing, B.D.R., J.W.M., and J.N.R.; Visualization, B.D.R., J.W.M., and Y.B.; Supervision, B.D.R.

**CONFLICTS OF INTEREST**

B.D.R. is the founder and CEO of AAVogen, which makes gene therapeutics for muscle wasting diseases. J.N.R. is a co-inventor of patents involving the micro-dystrophin gene therapeutics described herein. The other authors declare no competing interests.

**ACKNOWLEDGMENTS**

We thank the Viral Vector Core of the Seattle Wellstone Muscular Dystrophy Research Center for providing AAV vectors (NIH P50AR065139). This work was supported by grants to B.D.R. from the LGMD2I Research Fund and from the National Institutes of Health (R44CA221539). J.N.R. was also supported in part by a National Institutes of Health training grant (T32 GM007270).

**REFERENCES**

1. Michele, D.E., and Campbell, K.P. (2003). Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J. Biol. Chem. 278, 15457–15460.
2. Wheeler, M.T., Allikian, M.J., Heydemann, A., and McNally, E.M. (2002). The sarcoglycan complex in striated and vascular smooth muscle. Cold Spring Harb. Symp. Quant. Biol. 67, 389–397.
3. Roberts, R.G., Gardner, R.J., and Bobrow, M. (1994). Searching for the 1 in 2,400,000: a review of dystrophin gene point mutations. Hum. Mutat. 11, 15457–15460.
4. Romitti, P.A., Zhu, Y., Puzhankara, S., James, K.A., Nabukera, S.K., Zamba, G.K., Cialaloni, E., Cunniff, C., Druschel, C.M., Mathews, K.D., et al.; MD STARnet
23. Bostick, B., Shin, J.H., Yue, Y., and Duan, D. (2011). AAV-microdystrophin therapy for Duchenne muscular dystrophy. Mol. Ther. 26, 2337–2356.

22. Gregorevic, P., Blankinship, M.J., Allen, J.M., and Chamberlain, J.S. (2008). Systemic inhibition of myostatin in mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol. Dis. 32, 243–253.

21. Rocco, A.B., Levalley, J.C., Eldridge, J.A., Marsh, S.A., and Rodgers, B.D. (2014). AAV microdystrophin therapy for muscular dystrophy. Biochim. Biophys. Acta 1844, e28569.

20. Rocco, A.B., Levalley, J.C., Eldridge, J.A., Marsh, S.A., and Rodgers, B.D. (2014). AAV microdystrophin therapy for muscular dystrophy. Biochim. Biophys. Acta 1844, e28569.

19. Lai, Y., Yue, Y., and Duan, D. (2010). Evidence for the failure of adeno-associated virus type 5 to package a viral genome > or = 8.2 kb. Mol. Ther. 18, 75–79.

18. Lefaucheur, J.P., Pastoret, C., and Sebille, A. (1995). Phenotype of dystrophinopathy in old mdx mice. Anat. Rec. 235, 548–558.

17. De Luca, A., Pierno, S., Liantonio, A., Conte Camerino, D. (2003). Enhanced dystrophin expression in skeletal muscle of mdx dystrophic mdx mice. Mol. Ther.

16. Banks, G.B., Combs, A.C., Chamberlain, J.R., and Chamberlain, J.S. (2008). Molecular and cellular adaptations to chronic myostatin strain injury in mdx mice expressing a truncated dystrophin. Hum. Mol. Genet. 17, 3975–3986.

15. Banks, G.B., Judge, L.M., Allen, J.M., and Chamberlain, J.S. (2010). The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 6, e1000958.

14. Adams, M.E., Odom, G.L., Kim, M.J., Chamberlain, J.S., and Froehner, S.C. (2018). Neuronal nitric oxide synthase interacts with spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16-17. Hum. Mol. Genet.

13. Lai, Y., Zhao, J., Yue, Y., and Duan, D. (2013). #2 and #3 helices of dystrophin R16 and R17 frame a microdomain in the #1 helix of dystrophin R17 for neuronal NOS binding. Proc. Natl. Acad. Sci. USA 110, 525–530.

12. Lai, Y., Thomas, G.D., Yue, Y., Yang, H.T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J.S., Terjung, R.L., and Duan, D. (2009). Dystrophin carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest. 119, 624–635.

11. De Luca, A., Nico, B., Rolland, J.F., Coxoli, A., Burdi, R., Mangieri, D., Giannuzzi, V., Liantonio, A., Camerino, G.M., Splendore, V., Capogrosso, R.F., et al. (2009). Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J. Appl. Physiol. 106, 1311–1324.

10. Bars, R., Rolland, J.F., Frayse, B., Litvinova, K., Czollori, A., Giannuzzi, V., Liantonio, A., Camerino, G.M., Splendore, V., Capogrosso, R.F., et al. (2009). Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol. Dis. 32, 243–253.

9. Gao, Q.Q., and McNally, E.M. (2015). The dystrophin complex: structure, function, and implications for therapy. Compr. Physiol. 5, 1223–1239.

8. Lai, Y., Yue, Y., and Duan, D. (2010). Evidence for the failure of adeno-associated virus type 5 to package a viral genome > or = 8.2 kb. Mol. Ther. 18, 75–79.

7. Lefebvre, J.P., Pastoret, C., and Sebille, A. (1995). Phenotype of dystrophinopathy in old mdx mice. Nat. Genet. 9, 297–298.

6. Lefebvre, J.P., Pastoret, C., and Sebille, A. (1995). Phenotype of dystrophinopathy in old mdx mice. Nat. Genet.

5. Hoyał, M.A., Wisloff, U., Kemi, O.J., and Ellingsen, O. (2007). Running speed and maximal oxygen uptake in rats and mice: practical implications for exercise training. Eur. J. Cardiovasc. Prev. Rehabil 14, 753–760.

4. Hafstad, A.D., Boardman, N.T., Lund, J., Hauge, M., Khalid, A.M., Wisloff, U., Larsen, T.S., and Aasum, E. (2011). High intensity interval training alters substrate utilization and reduces oxygen consumption in the heart. J. Appl. Physiol. 111, 1235–1241.

3. Maricelli, J.W., Kaged, D.R., Bishaw, Y.M., Nelson, O.L., Lin, D.C., and Rodgers, B.D. (2017). Sexually dimorphic skeletal muscle and cardiac dysfunction in a mouse model of limb girdle muscular dystrophy 2i. J. Appl. Physiol. (1985) 123, 1126–1138.

2. Burdi, R., Rolland, J.F., Frayse, B., Litvinova, K., Czollori, A., Giannuzzi, V., Liantonio, A., Camerino, G.M., Splendore, V., Capogrosso, R.F., et al. (2009). Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests. J. Appl. Physiol.
with follistatin improves the success of myoblast transplantation in dystrophic mice. Cell Transplant. 17, 337–350.

44. Benabdallah, B.F., Boucenhout, M., and Tremblay, J.P. (2005). Improved success of myoblast transplantation in mdx mice by blocking the myostatin signal. Transplantation 79, 1696–1702.

45. Byron, C.D., Hanrick, M.W., and Wingard, C.J. (2006). Alterations of temporalis muscle contractile force and histological content from the myostatin and Mdx deficient mouse. Arch. Oral Biol. 51, 396–405.

46. Hulmi, J.J., Oliveira, B.M., Silvennoinen, M., Hoogaars, W.M., Ma, H., Pierre, P., Pasternack, A., Painulainen, H., and Ritvos, O. (2013). Muscle protein synthesis, mTORC1/MAFKE/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. Am. J. Physiol. Endocrinol. Metab. 304, E41–E50.

47. Morine, K.J., Bish, L.T., Selsby, J.T., Gazzara, J.A., Pendrak, K., Sleeper, M.M., Barton, E.R., Lee, S.J., and Sweeney, H.L. (2010). Activin IB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve 42, 722–730.

48. Wagner, K.R., McPherron, A.C., Wink, N., and Lee, S.J. (2002). Loss of myostatin attenuates severity of muscular dystrophy in mdx mice. Ann. Neurol. 52, 832–836.

49. National Institutes of Health. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=ace-031.

50. Plumridge, H., and Falconi, M. (2014). Drugs aim to help elderly rebuild muscle. Wall Street Journal, April 27, 2014, https://www.wsj.com/articles/drugs-aims-to-help-elderly-rebuild-muscle-1498644791.

51. Garber, K. (2016). No longer going to waste. Nat. Biotechnol. 34, 458–461.

52. Maricelli, J.W., Bishaw, Y.M., Wang, B., Du, M., and Rodgers, B.D. (2018). Systemic Smad7 gene therapy increases striated muscle mass and enhances exercise capacity in a dose-dependent manner. Hum. Gene Ther 29, 390–399.

53. Winbanks, C.E., Murphy, K.T., Bernardo, B.C., Qian, H., Liu, Y., Sepulveda, P.V., Beyer, C., Hagg, A., Thomson, R.E., Chen, J.L., et al. (2016). Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci. Transl. Med. 8, 348ra98.

54. Hakim, C.H., Wasala, N.B., Pan, X., Kodippili, K., Yue, Y., Zhang, K., Yao, G., Haffner, B., Duan, S.X., Ramos, J., et al. (2017). A five-repeat micro-dystrophin gene ameliorated dystrophic phenotype in the severe DBA/2J-mdx model of Duchenne muscular dystrophy. Mol. Ther. Methods Clin. Dev. 6, 216–230.

55. Hiltun, T., Orr, R.D., Perkin, R.M., and Ashwal, S. (1993). End of life care in Duchenne muscular dystrophy. Pediatr. Neurol. 9, 165–177.

56. Van Ruiten, H.I., Marini Bettolo, C., Cheetham, T., Eagle, M., Lochmuller, H., Straub, V., Bushby, K., and Guglielmi, M. (2016). Why are some patients with Duchenne muscular dystrophy dying young: an analysis of causes of death in North East England. Eur. J. Paediatr. Neurol. 20, 904–909.

57. Bassett, D.R., Jr., and Howley, E.T. (2000). Limiting factors for maximum oxygen uptake and determinants of endurance performance. Med. Sci. Sports Exerc. 32, 70–84.

58. Ciafaloni, E., Fox, D.J., Pandya, S., Westfield, C.P., Puzhankara, S., Romitti, P.A., Mathews, K.D., Miller, T.M., Matthews, D.J., Miller, L.A., et al. (2009). Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J. Pediatr. 155, 380–385.

59. Mohamed, K., Appleton, R., and Nicolaides, P. (2000). Delayed diagnosis of Duchenne muscular dystrophy. Eur. J. Paediatr. Neurol. 4, 219–223.

60. Wong, S.H., McClaren, B.J., Archibald, A.D., Weeks, A., Langmaid, T., Ryan, M.M., Kornberg, A., and Metcalfe, S.A. (2015). A mixed methods study of age at diagnosis and diagnostic odyssey for Duchenne muscular dystrophy. Eur. J. Hum. Genet. 23, 1294–1300.

61. Salva, M.Z., Himeda, C.L., Tai, P.W., Nishitani, E., Gregorevic, P., Allen, J.M., Finn, E.E., Nguyen, Q.G., Blakinship, M.I., Meuse, L., et al. (2007). Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol. Ther. 15, 320–329.

62. Himeda, C.L., Chen, X., and Hauschka, S.D. (2011). Design and testing of regulatory cassettes for optimal activity in skeletal and cardiac muscles. Methods Mol. Biol. 709, 3–19.

63. Gonçalves, M.A., Janssen, J.M., Nguyen, Q.G., Athanasopoulos, T., Hauschka, S.D., Dickson, G., and de Vries, A.A. (2011). Transcription factor rational design improves directed differentiation of human mesenchymal stem cells into skeletal myocytes. Mol. Ther. 19, 1331–1341.

64. Martari, M., Sagazio, A., Mohamadi, A., Nguyen, Q., Hauschka, S.D., Kim, E., and Salvatori, R. (2009). Partial rescue of growth failure in growth hormone (GH)-deficient mice by a single injection of a double-stranded adenovirus-associated viral vector expressing the GH gene driven by a muscle-specific regulatory cassette. Hum. Gene Ther. 20, 759–766.

65. Bengtsson, N.E., Seto, J.T., Hall, J.K., Chamberlain, I.S., and Odom, G.L. (2016). Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum. Mol. Genet. 25 (R1), R9–R17.

66. Hu, C., Kasten, J., Park, H., Bhargava, R., Tai, D.S., Grody, W.W., Nguyen, Q.G., Hauschka, S.D., Cederna, S.D., and Lipshtiz, G.S. (2014). Myocyte-mediated arginine expression controls hyperargininemia but not hyperammonemia in arginase-deficient mice. Mol. Ther. 22, 1792–1802.

67. Muir, L.A., Nguyen, Q.G., Hauschka, S.D., and Chamberlain, J.S. (2014). Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle. Mol. Ther. Methods Clin. Dev. 1, 14025.

68. Le Rumeur, E., Winder, S.J., and Hubert, J.F. (2010). Dystrophin: more than just the sum of its parts. Biochim. Biophys. Acta 1804, 1713–1722.